Castle Biosciences, Inc.

NasdaqGM:CSTL Stock Report

Market Cap: US$765.2m

Castle Biosciences Dividends and Buybacks

Dividend criteria checks 0/6

Castle Biosciences does not have a record of paying a dividend.

Key information

n/a

Dividend yield

0.2%

Buyback Yield

Total Shareholder Yield0.2%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Castle Biosciences (NASDAQ:CSTL) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Dec 12
Castle Biosciences (NASDAQ:CSTL) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?

Oct 15
Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?

Castle Biosciences: Inflection Into Profitability

Aug 16

Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts

Aug 11
Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts

Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Aug 08
Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up

Aug 04
Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up

Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?

Jul 12
Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?

Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark

Apr 30
Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark

Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Jan 27
Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Oct 31
Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Jun 13
Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if CSTL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CSTL's dividend payments have been increasing.

Dividend Yield vs Market

Castle Biosciences Dividend Yield vs Market
How does CSTL dividend yield compare to the market?
SegmentDividend Yield
Company (CSTL)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.4%
Industry Average (Healthcare)1.9%
Analyst forecast (CSTL) (up to 3 years)n/a

Notable Dividend: Unable to evaluate CSTL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CSTL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate CSTL's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CSTL has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/16 14:25
End of Day Share Price 2025/02/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Castle Biosciences, Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Mark MassaroBTIG
Kyle MiksonCanaccord Genuity